Case Report: Significant Response to the Combination of Lenvatinib and Immune Checkpoint Inhibitor in a Patient With Heavily Pretreated Metastatic Triple Negative Breast Cancer

by Jin Sun Lee, Susan E. Yost, Yuan Yuan
Published 2021-01-01

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges

by Jin Sun Lee, Susan E. Yost, Yuan Yuan
Published 2020-05-01

Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes

by Jasmine A. McQuerry, David F. Jenkins, Susan E. Yost, Yuqing Zhang, Daniel Schmolze, W. Evan Johnson, Yuan Yuan, Andrea H. Bild
Published 2019-09-01

Analysis of Gut Microbiome Using Explainable Machine Learning Predicts Risk of Diarrhea Associated With Tyrosine Kinase Inhibitor Neratinib: A Pilot Study

by Chi Wah Wong, Susan E. Yost, Jin Sun Lee, John D. Gillece, Megan Folkerts, Lauren Reining, Sarah K. Highlander, Zahra Eftekhari, Joanne Mortimer, Yuan Yuan
Published 2021-03-01

Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer

by Wei Wen, Emily Marcinkowski, David Luyimbazi, Thehang Luu, Quanhua Xing, Jin Yan, Yujun Wang, Jun Wu, Yuming Guo, Dylan Tully, Ernest S. Han, Susan E. Yost, Yuan Yuan, John H. Yim
Published 2019-08-01

Multi-panel immunofluorescence analysis of tumor infiltrating lymphocytes in triple negative breast cancer: Evolution of tumor immune profiles and patient prognosis.

by Ting-Fang He, Susan E Yost, Paul H Frankel, Andrew Dagis, Yu Cao, Roger Wang, Anthony Rosario, Travis Yiwey Tu, Shawn Solomon, Daniel Schmolze, Joanne Mortimer, Peter Lee, Yuan Yuan
Published 2020-01-01

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer

by Zi-Ming Zhao, Susan E. Yost, Katherine E. Hutchinson, Sierra Min Li, Yate-Ching Yuan, Javad Noorbakhsh, Zheng Liu, Charles Warden, Radia M. Johnson, Xiwei Wu, Jeffrey H. Chuang, Yuan Yuan
Published 2019-01-01

Mutation and immune profiling of metaplastic breast cancer: Correlation with survival.

by Michelle Afkhami, Daniel Schmolze, Susan E Yost, Paul H Frankel, Andrew Dagis, Idoroenyi U Amanam, Milhan Telatar, Kim Nguyen, Kim Wai Yu, Thehang Luu, Raju Pillai, Patricia A Aoun, Joanne Mortimer, Yuan Yuan
Published 2019-01-01

Spatial distribution of B cells and lymphocyte clusters as a predictor of triple-negative breast cancer outcome

by Juliana C. Wortman, Ting-Fang He, Shawn Solomon, Robert Z. Zhang, Anthony Rosario, Roger Wang, Travis Y. Tu, Daniel Schmolze, Yuan Yuan, Susan E. Yost, Xuefei Li, Herbert Levine, Gurinder Atwal, Peter P. Lee, Clare C. Yu
Published 2021-07-01

Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer

by Jin Sun Lee, Susan E. Yost, Suzette Blanchard, Daniel Schmolze, Hongwei Holly Yin, Raju Pillai, Kim Robinson, Aileen Tang, Norma Martinez, Jana Portnow, Wei Wen, John H. Yim, Heather Ann Brauer, Yuqi Ren, Thehang Luu, Joanne Mortimer, Yuan Yuan
Published 2019-11-01

Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients

by Moom R. Roosan, Isa Mambetsariev, Rebecca Pharaon, Jeremy Fricke, Angel R. Baroz, Joseph Chao, Chen Chen, Mohd W. Nasser, Ramakanth Chirravuri-Venkata, Maneesh Jain, Lynette Smith, Susan E. Yost, Karen L. Reckamp, Raju Pillai, Leonidas Arvanitis, Michelle Afkhami, Edward W. Wang, Vincent Chung, Mihaela Cristea, Marwan Fakih, Marianna Koczywas, Erminia Massarelli, Joanne Mortimer, Yuan Yuan, Surinder K. Batra, Sumanta Pal, Ravi Salgia
Published 2021-06-01